Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function - Trial NCT06039254
Access comprehensive clinical trial information for NCT06039254 through Pure Global AI's free database. This Phase 1 trial is sponsored by Shandong Suncadia Medicine Co., Ltd. and is currently Not yet recruiting. The study focuses on Chronic Kidney Disease. Target enrollment is 27 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shandong Suncadia Medicine Co., Ltd.
Timeline & Enrollment
Phase 1
Sep 01, 2023
Dec 08, 2023
Primary Outcome
Pharmacokinetics-Cmax,Pharmacokinetics-AUC0-last,Pharmacokinetics-AUC0-inf
Summary
This is a multicenter, non-randomized, open-label, parallel-controlled study. The main
 objective is to evaluate the safety and pharmacokinetics of HRS-1780 in subjects with mild
 and moderate renal impairment versus healthy subjects, and to provide a basis for dose
 selection of HRS-1780 in patients with chronic kidney disease.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06039254
Non-Device Trial